跳至主要内容
临床试验/JPRN-UMIN000029838
JPRN-UMIN000029838尚未招募未知

Treatment of plasminogen activator in ophthalmology - Treatment of t-PA in ophthalmology

Department of Ophthalmology, Kanazawa University0 个研究点目标入组 10 人开始时间: 2017年11月6日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • (1)Patients who are during lactation or pregnancy or expected pregnancy (2)Patients who have active eye/eyelid inflammation or disease or infection (3)Patients who have hemorrhagic diathesis (4)Patients who are judged to be inappropriate for this trial by the judgement of the doctor.

研究者

发起方
Department of Ophthalmology, Kanazawa University

相似试验

进行中(未招募)
1 期
A clinical trial of a clot dissolving drug and gas, injected into the eye, to treat bleeding associated with wet age-related macular degeneratioSub-macular haemorrhage secondary to wet macular degenerationMedDRA version: 16.0Level: PTClassification code 10064930Term: Age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersMedDRA version: 16.0Level: LLTClassification code 10067791Term: Wet macular degenerationSystem Organ Class: 10015919 - Eye disorders
EUCTR2012-004078-24-GBKing's College London
进行中(未招募)
1 期
Vitrectomy and subretinal TPA for submacular haemorrhage secondary to wet AMD (TIGER).Exudative age-related macular degenerationMedDRA version: 20.0Level: LLTClassification code: 10075718Term: Exudative age-related macular degeneration Class: 10015919
CTIS2023-504751-28-00King's College London90
进行中(未招募)
1 期
A study of surgery to clear bleeding due to age-related macular degeneration.
EUCTR2020-004917-10-DEKing's College London210
已完成
不适用
Recombinant tissue Plasminogen Activator administration by retinal branch vein route for Central Retinal Vein Occlusion: a randomised conventional therapy controlled trialCentral Retinal Vein Occlusion (CRVO)Eye Diseases
ISRCTN58543190Oogziekenhuis Rotterdam (OZR) (The Netherlands)48
已完成
不适用
Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularizatioSubfoveal type 2 choroidal neovascularization
JPRN-UMIN000016870agoya City University Graduate School of Medicine20